Mon, Oct 20, 2014, 1:25 AM EDT - U.S. Markets open in 8 hrs 5 mins

Recent

% | $
Quotes you view appear here for quick access.

Gilead Sciences Inc. Message Board

  • CD3313 CD3313 Jun 15, 2007 6:22 PM Flag

    The Barber Blew IT AGAIN!!!

    I said in February that Ambrisentan (now known as Letairis) would be APRROVED by the FDA.

    After you dogdged the question 3 TIMES, you FINALLY stated for the record that Ambrisentan would not approved by the FDA by June 18, but would receive an approveABLE letter. Since backing yourself into that corner, you've consistently bashed Gilead on this thread.....YOU LOSE!!!!!

    Today, the FDA approved once-daily Letairis 5mg AND 10mg for the treatment of PAH. THE FUNCTIONAL CLASS II AND III APPROVAL COVERS 80% OF THE DIAGNOSED POPULATION. Of that population, 90% are on treatment. The cost for a 30-day supply of Letairis is $3,940. Gilead is sponsoring an access program for Letairis and will continue studying the product in Phase IV studies to further expand its label.

    Gilead KNOWS how to grow a market.

    ENCY (and Southclown) are TOAST!


    Thank you and Congratulations to the AWESOME management team and employees of Gilead Sciences!!!



    LONG AND STRONG

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • a week ago ENCY WAS TOAST!!!!!!!!!!!!!!!!!!!!!!!!

    • You think so? Too bad you received a BLACK BOX with limited distribution.

    • pkornie@sbcglobal.net pkornie Jun 15, 2007 6:41 PM Flag

      << The Barber Blew IT AGAIN!!! (1 Rating) 16 minutes ago I said in February that Ambrisentan (now known as Letairis) would be APRROVED by the FDA.

      After you dogdged the question 3 TIMES, you FINALLY stated for the record that Ambrisentan would not approved by the FDA by June 18, but would receive an approveABLE letter. Since backing yourself into that corner, you've consistently bashed Gilead on this thread.....YOU LOSE!!!!!

      Today, the FDA approved once-daily Letairis 5mg AND 10mg for the treatment of PAH. THE FUNCTIONAL CLASS II AND III APPROVAL COVERS 80% OF THE DIAGNOSED POPULATION. Of that population, 90% are on treatment. The cost for a 30-day supply of Letairis is $3,940. Gilead is sponsoring an access program for Letairis and will continue studying the product in Phase IV studies to further expand its label.

      Gilead KNOWS how to grow a market.

      ENCY (and Southclown) are TOAST!


      Thank you and Congratulations to the AWESOME management team and employees of Gilead Sciences!!!



      LONG AND STRONG


      Sentiment : Strong Buy
      You have rated >>*****

    • Your creds were always higher than the barber CD, your posts far more enlightening.

      I read all the studies, and the ENCY studies too. I've been increasing my GILD holdings on every Down Market.

      I was never even slightly worried about what that foolish barber had to say. He couldn't even understand the science of what he was reading.

 
GILD
100.75+3.87(+3.99%)Oct 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.